Faculty Profiles - KAWAKAMI Yoshio

Papers - KAWAKAMI Yoshio

Division display 1 - 20 of about 124 ／ All the affair displays >>

Monokine induced by gamma interferon levels in plasma might be a diagnostic marker of Hydroa vaccniforme lymphoproliferative disorder systemic form. International journal

Tomoko Miyake, Takenobu Yamamoto, Yoji Hirai, Takahide Takahashi, Takuya Furuhashi, Hisashi Nomura, Yoshio Kawakami, Shin Morizane

Journal of the American Academy of Dermatology 2024.11

A case of anaphylaxis to kumquat (Citrus japonica). International journal

Shogo Ikezawa, Emi Yokoyama, Hitoshi Urakami, Mikiko Takigawa, Tomoko Miyake, Yoji Hirai, Yoshio Kawakami, Shin Morizane

European journal of dermatology : EJD 34 ( 5 ) 539 - 541 2024.10

特集膠原病脱毛から診断に至った高齢期発症の全身性エリテマトーデスの1例

松本真理, 横山恵美, 川上佳夫, 勝山恵理, 山口春佳, 森実真

皮膚科の臨床 66 ( 9 ) 1207 - 1210 2024.8

The treatment effect of endovascular therapy for chronic limb-threatening ischemia with systemic sclerosis. International journal

Yoshihiro Matsuda, Tomoko Miyake, Hironobu Toda, Kota Tachibana, Hayato Nomura, Yoji Hirai, Yoshio Kawakami, Naoya Sakoda, Shin Morizane

The Journal of dermatology 51 ( 8 ) 1108 - 1112 2024.8

Language：English Publishing type：Research paper (scientific journal)

Systemic sclerosis (SSc) is a collagen disease with immune abnormalities, vasculopathy, and fibrosis. Ca blockers and prostaglandins are used to treat peripheral circulatory disturbances. Chronic limb-threatening ischemia (CLTI) is a disease characterized by extremity ulcers, necrosis, and pain due to limb ischemia. Since only a few patients present with coexistence of CLTI and SSc, the treatment outcomes of revascularization in these cases are unknown. In this study, we evaluated the clinical characteristics and treatment outcomes of seven patients with CLTI and SSc, and 35 patients with uncomplicated CLTI who were hospitalized from 2012 to 2022. A higher proportion of patients with uncomplicated CLTI had diabetes and male. There were no significant differences in the age at which ischemic ulceration occurred, other comorbidities, or in treatments, including antimicrobial agents, revascularization and amputation, improvement of pain, and the survival time from ulcer onset between the two subgroups. EVT or amputation was performed in six or two of the seven patients with CLTI and SSc, respectively. Among those who underwent EVT, 33% (2/6) achieved epithelialization and 67% (4/6) experienced pain relief. These results suggest that the revascularization in cases with CLTI and SSc should consider factors such as infection and general condition, since revascularization improve the pain of these patients.

DOI： 10.1111/1346-8138.17334

PubMed

researchmap

Acquired generalized anhidrosis following durvalumab treatment in a patient with advanced non-small cell lung cancer. International journal

Yuko Fujimoto, Yoshio Kawakami, Tomoko Miyake, Yoji Hirai, Masahiro Tabata, Shin Morizane

The Journal of dermatology 2024.7

A Gardner-Diamond Syndrome Accompanied by Complex Regional Pain Syndrome

Emi Yokoyama, Yoshio Kawakami, Ayumi Okada, Masato Yashiro, Tomoko Tetsunaga, Shin Morizane

Indian Journal of Dermatology 69 ( 4 ) 350 - 352 2024.7

Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma. International journal

Yoji Hirai, Jun Sakurai, Shiho Yoshida, Takashi Kikuchi, Toshiharu Mitsuhashi, Tomoko Miyake, Taku Fujimura, Riichiro Abe, Hiroki Fujikawa, Hikari Boki, Hiraku Suga, Sayaka Shibata, Tomomitsu Miyagaki, Takatoshi Shimauchi, Eiji Kiyohara, Yoshio Kawakami, Shin Morizane

The Journal of dermatology 2024.6

Language：English Publishing type：Research paper (scientific journal)

Brentuximab vedotin (BV), a conjugate of anti-CD30 antibody and monomethyl auristatin E, has emerged as a promising treatment option for refractory CD30+ mycosis fungoides (MF) and primary cutaneous anaplastic large-cell lymphoma (pcALCL). BV has been shown to be safe and effective in treating Hodgkin's lymphoma and peripheral T-cell lymphoma. This multicenter, prospective, single-arm phase I/II study evaluated the efficacy of BV in Japanese patients with CD30+ cutaneous lymphomas, namely CD30+ cutaneous T-cell lymphoma. Participants were divided into two groups: those with CD30+ MF or pcALCL (cohort 1, n = 13) and those with CD30+ lymphoproliferative disorders other than those in cohort 1 (cohort 2, n = 3). The studied population included the full analysis set (FAS), modified FAS (mFAS), and safety analysis set (SAF). These sets were identified in cohorts 1 and 1 + 2 and labeled FAS1 and FAS2, mFAS1 and mFAS2, and SAF1 and SAF2, respectively. Each treatment cycle lasted 3 weeks, and BV was continued for up to 16 cycles after the third cycle based on treatment response. The primary endpoint was the 4-month objective response rate (ORR4) determined by the Independent Review Forum (IRF). ORR4 was 69.2% for FAS1 and 62.5% for FAS2 (P < 0.0001). Secondary endpoints of ORR, assessed using the global response score (53.8% in FAS1) and modified severity-weighted assessment tool (62.5% in FAS1), using the IRF, provided results comparable to the primary findings. The incidence of ≥grade 3 adverse events (≥15%) in SAF1 was peripheral neuropathy in three patients (23%) and fever and eosinophilia in two patients (15%). In conclusion, BV showed favorable efficacy, tolerability, and safety profile in Japanese patients with relapsed or refractory CD30+ primary cutaneous T-cell lymphoma. The trial was registered with University Hospital Medical Information Network Clinical Trials Registry, Japan (protocol ID: UMIN000034205).

DOI： 10.1111/1346-8138.17324

PubMed

researchmap

Disseminated Lomentospora prolificans infection presenting with multiple cutaneous lesions in an immunocompromised host: A case report and literature review. International journal

Masaya Kawamoto, Yoshio Kawakami, Yoji Hirai, Saya Kubota, Hideaki Fujiwara, Yayoi Ueda, Kazushi Anzawa, Yoshinobu Maeda, Shin Morizane

The Journal of dermatology 2024.6

前頭部皮下腫瘤として術後再発した髄膜腫の1例

砂川滉, 神野泰輔, 三宅智子, 川上佳夫, 森実真, 藤井謙太郎

日本皮膚科学会雑誌 134 ( 7 ) 1920 - 1920 2024.6

Enfortumab vedotin投与後に四肢に水疱性病変を呈した2例

村田愛美, 蓮井謙一, 松田吉弘, 横溝紗佑里, 岡野真理, 三宅智子, 平井陽至, 川上佳夫, 森実真

西日本皮膚科 86 ( 3 ) 314 - 314 2024.6

オトガイ部の生検から診断に至った全身性ALアミロイドーシスの1例

坂田伽奈子, 川上佳夫, 横山恵美, 森実真, 長谷川功, 中野靖浩, 大塚文男, 白藤宜紀

日本皮膚科学会雑誌 134 ( 6 ) 1711 - 1711 2024.5

難治性下腿潰瘍の精査により診断したKlinefelter症候群の1例

川本雅也, 三宅智子, 神野泰輔, 高須賀琴巳, 別木祐介, 松本真理, 澤井希望, 川上佳夫, 森実真, 淺田騰, 戸田洋伸

日本皮膚科学会雑誌 134 ( 6 ) 1711 - 1711 2024.5

抗PD-L1抗体投与後にirAEとして無汗症を発症した1例

藤本裕子, 川上佳夫, 三宅智子, 平井陽至, 森実真, 田端雅弘

日本皮膚科学会雑誌 134 ( 5 ) 1557 - 1557 2024.5

外陰部病変を伴ったクローン病の1例

梶田藍, 川上佳夫, 平岡佐規子, 平賀順子, 森実真

西日本皮膚科 86 ( 2 ) 192 - 192 2024.4

NVX-CoV2373ワクチン投与後に血管浮腫様の眼瞼浮腫を生じた1例

松本真理, 川上佳夫, 三宅智子, 平井陽至, 森実真, 片岡仁美, 大塚文男

西日本皮膚科 86 ( 2 ) 198 - 198 2024.4

Elevated expression of interleukin‐6 (<scp>IL</scp>‐6) and serum amyloid A (<scp>SAA</scp>) in the skin and the serum of recessive dystrophic epidermolysis bullosa: Skin as a possible source of <scp>IL</scp>‐6 through Toll‐like receptor ligands and <scp>SAA</scp> Reviewed

Yoshio Kawakami, Ai Kajita, Ken‐Ichi Hasui, Yoshihiro Matsuda, Keiji Iwatsuki, Shin Morizane

Experimental Dermatology 33 ( 3 ) 2024.3

Authorship：Lead author Publishing type：Research paper (scientific journal) Publisher：Wiley

Abstract

The effect of persistent skin inflammation on extracutaneous organs and blood is not well studied. Patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe form of the inherited blistering skin disorder, have widespread and persistent skin ulcers, and they develop various complications including anaemia, hyperglobulinaemia, hypoalbuminaemia and secondary amyloidosis. These complications are associated with the bioactivities of IL‐6, and the development of secondary amyloidosis requires the persistent elevation of serum amyloid A (SAA) level. We found that patients with RDEB had significantly higher serum levels of IL‐6 and SAA compared to healthy volunteers and patients with psoriasis or atopic dermatitis. Both IL‐6 and SAA were highly expressed in epidermal keratinocytes and dermal fibroblasts of the skin ulcer lesions. Keratinocytes and fibroblasts surrounding the ulcer lesions are continuously exposed to Toll‐like receptor (TLR) ligands, pathogen‐associated and damage‐associated molecular pattern molecules. In vitro, TLR ligands induced IL‐6 expression via NF‐κB in normal human epidermal keratinocytes (NHEKs) and dermal fibroblasts (NHDFs). SAA further induced the expression of IL‐6 via TLR1/2 and NF‐κB in NHEKs and NHDFs. The limitation of this study is that NHEKs and NHDFs were not derived from RDEB patients. These observations suggest that TLR‐mediated persistent skin inflammation might increase the risk of IL‐6‐related systemic complications, including RDEB.

File： Kawakami-2024-Elevated-expression-of-interleukin-.pdf

DOI： 10.1111/exd.15040

researchmap

ヒアルロン酸注入により下顎部に異物肉芽腫を生じた1例

坂田伽奈子, 神野泰輔, 川上佳夫, 森実真, 柳井広之

日本皮膚科学会雑誌 134 ( 2 ) 351 - 352 2024.2

メトトレキサート内服と圧迫療法が奏功した下腿の潰瘍型皮膚サルコイドーシス

前琴絵, 川上佳夫, 三宅智子, 平井陽至, 森実真, 品岡玲, 廣瀬梓

西日本皮膚科 86 ( 1 ) 89 - 89 2024.2

メトトレキサート内服と圧迫療法が奏効した下腿潰瘍を伴ったサルコイドーシスの1例

65 ( 13 ) 2044 - 2047 2023.12

キンカンによるアナフィラキシーの1例

池澤勝吾, 横山恵美, 浦上仁志, 瀧川充希子, 三宅智子, 平井陽至, 川上佳夫, 森実真

日本皮膚免疫アレルギー学会総会学術大会プログラム・抄録集 53回 201 - 201 2023.12

　 PREV - NEXT 　

< KAWAKAMI Yoshio >

Papers - KAWAKAMI Yoshio